1
|
Goodstein T, Goldberg I, Acikgoz Y, Hasanov E, Srinivasan R, Singer EA. Special populations in metastatic renal cell carcinoma. Curr Opin Oncol 2024; 36:186-194. [PMID: 38573208 DOI: 10.1097/cco.0000000000001028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2024]
Abstract
PURPOSE OF REVIEW This review focuses on special populations poorly represented in current evidence-based practice for metastatic renal cell carcinoma (mRCC). This includes the elderly and frail, patients on immunosuppression or with autoimmune diseases, patients with brain, liver, and/or bone metastases, and RCC with sarcomatoid features. RECENT FINDINGS Certain populations are poorly represented in current trials for mRCC. Patients with central nervous system (CNS) metastases are often excluded from first-line therapy trials. Modern doublet systemic therapy appears to benefit patients with bone or liver metastases, but data supporting this conclusion is not robust. Post-hoc analyses on patients with sarcomatoid differentiation have shown improved response to modern doublet therapy over historical treatments. The elderly are underrepresented in current clinical trials, and most trials exclude all but high-performing (nonfrail) patients, though true frailty is likely poorly captured using the current widely adopted indices. It is difficult to make conclusions about the efficacy of modern therapy in these populations from subgroup analyses. Data from trials on other malignancies in patients with autoimmune diseases or solid organ transplant recipients on immunosuppression suggest that immune checkpoint inhibitors (ICIs) may still have benefit, though at the risk of disease flare or organ rejection. The efficacy of ICIs has not been demonstrated specifically for RCC in this group of patients. SUMMARY The elderly, frail, and immunosuppressed, those with tumors having aggressive histologic features, and patients with brain, bone, and/or liver metastases represent the populations least understood in the modern era of RCC treatment.
Collapse
Affiliation(s)
- Taylor Goodstein
- Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
| | - Ilana Goldberg
- Division of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
| | - Yusuf Acikgoz
- Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
| | - Elshad Hasanov
- Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
| | - Ramaprasad Srinivasan
- Molecular Therapeutics Section, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Eric A Singer
- Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
| |
Collapse
|
2
|
Wilson NR, Acikgoz Y, Hasanov E. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options. Int J Cancer 2024; 154:947-961. [PMID: 37823185 DOI: 10.1002/ijc.34756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 09/15/2023] [Accepted: 09/19/2023] [Indexed: 10/13/2023]
Abstract
Non-clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. Compared to clear-cell RCC (ccRCC), nccRCC typically has a worse prognosis in the metastatic setting, with overall survival durations that are ~10 months shorter. The nccRCC consists of a wide range of different histological subtypes, the majority of which are composed of papillary, chromophobe, renal medullary carcinoma, translocation RCC, collecting duct carcinoma and unclassified RCC. Most clinical trials have either excluded or only included small numbers of patients with nccRCC; owing to the lack of prospective studies focusing on this population, data on response rates and survival outcomes are lacking. NccRCC treatment is a nascent field with various therapeutic modalities and combinations under investigation, often based on data extrapolated from therapeutic studies in ccRCC. We herein review the use and outcomes of cytotoxic chemotherapy, various combination modalities of tyrosine kinase inhibitors and immune checkpoint inhibitors, and targeted agents. We discuss active ongoing clinical trials for patients with nccRCC and future directions in the treatment of this rare disease. Historically, treatment for nccRCC has been adopted from the standard of care for patients with ccRCC, although these treatments are less effective in the nccRCC population. As we begin to understand the underlying biology of these tumors, clinical trials have been able to slowly accrue and include more patients with various subtypes of nccRCC. There remains much room for improvement in this area of need, but there is hope on the horizon.
Collapse
Affiliation(s)
- Nathaniel R Wilson
- Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan; Michigan Medicine, Ann Arbor, Michigan, USA
| | - Yusuf Acikgoz
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
| | - Elshad Hasanov
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
- Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
| |
Collapse
|
3
|
Acikgoz Y, Yildirim FU, Esen SA, Ucar G, Ergun Y, Bal O, Dogan M, Uncu D. The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer. Am J Clin Oncol 2023; 46:543-550. [PMID: 37700432 DOI: 10.1097/coc.0000000000001044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/14/2023]
Abstract
OBJECTIVE We represent Sprouty 2 (Spry2) expression analysis and its association with key driver mutations and clinical features of patients with non-small cell lung cancer as the largest ex vivo data. METHODS The strength of Spry2 expression was evaluated using the immunoreactivity score (IRS), which was calculated using the following formula: IRS=(staining intensity score) SI×(percentage of positively stained cells) PP. The median IRS score was defined as the cutoff value. Patients were grouped as "weak immunoreactivity score" (IRS: 0 to 4) or "strong immunoreactivity score" (IRS: ≥4) with respect to the IRS score. RESULTS The intensity and percentage of Spry2 staining were significantly lower in tumor tissues than in normal lung tissues ( P <0.0001). Patients' characteristics were similar for both groups, except for smoking status and, brain and lymph node metastasis. Overall survival of patients with a strong immunoreactivity score was significantly lower than those with a weak immunoreactivity score among metastatic patients (6.9 mo vs. 13.6, P =0.023) and adenocarcinoma histology (7.0 mo vs. not reached, P =0.003). CONCLUSION Spry2 expression was lower in tumor tissues than in normal lung parenchyma. Increased expression of Spry2 is associated with poor prognosis. There were no significant associations between epidermal growth factor receptor, anaplastic lymphoma kinase, or c-ros oncogene 1 rearrangement and Spry2 expression. Despite the absence of KRAS mutational analysis, the clinical and epidemiological features of patients suggested that KRAS mutation might be an underlying determinant factor of the functional role of Spry2 in non-small cell lung cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Mutlu Dogan
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey
| | | |
Collapse
|
4
|
Caliskan Yildirim E, Acikgoz Y, Ergun Y, Algin E, Bal O. Treatment Outcomes and Prognostic Factors in N3 Stage Gastric Cancer After Curative Resection: A Real World Data. Cancer Manag Res 2023; 15:1085-1096. [PMID: 37809035 PMCID: PMC10559796 DOI: 10.2147/cmar.s412270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 09/21/2023] [Indexed: 10/10/2023] Open
Abstract
Purpose N3 gastric cancer is characterized by a fairly high lymph node metastasis burden and poor outcome despite optimal therapy. Given the limitations of TNM classification, a comprehensive evaluation tool is necessary to predict the prognosis of patients with N3 gastric cancer who underwent curative surgery. This study aims to explore the outcomes and clinicopathologic prognostic factors affecting the overall survival (OS) of patients with N3 gastric cancer after surgery. Methods Data on patients with N3 gastric cancer who underwent (sub)total gastrectomy and regional lymph node dissection between November 2005 and September 2018 (n = 169) were analyzed by Cox regression to determine the independent prognostic factors for OS. Results The multivariable analysis established that gender, patient performance status, metastatic lymph node ratio (MLNR), tumor grade, and adjuvant chemotherapy are significantly associated with OS. The five-year OS of the study population was 15%. Adjuvant chemoradiotherapy was applied to 72% of the patients, which resulted in an improvement in recurrence-free survival but not OS. Recurrence occurred in 103 (75%) patients, in which the most frequent recurrence site was distant metastasis. Conclusion Male gender, poor performance status, grade 3 tumor, MLNR > 0.37, and not receiving adjuvant chemotherapy are predictors of poor prognosis in N3 gastric cancer after curative resection. Considering the high recurrence rates of this group, prospective studies are needed to optimize treatment strategies.
Collapse
Affiliation(s)
- Eda Caliskan Yildirim
- Dokuz Eylul University, Department of Internal Medicine, Division of Medical Oncology, Izmir, Turkey
| | - Yusuf Acikgoz
- Health Sciences University Ankara City Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Yakup Ergun
- Health Sciences University Ankara City Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Efnan Algin
- Health Sciences University Ankara City Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Oznur Bal
- Health Sciences University Ankara City Hospital, Department of Medical Oncology, Ankara, Turkey
| |
Collapse
|
5
|
Algin E, Esen SA, Acikgoz Y, Bal O. The effectiveness of adjuvant treatment approaches for resectable esophageal cancer: A single-center experience. J Cancer Res Ther 2023; 19:2018-2024. [PMID: 38376312 DOI: 10.4103/jcrt.jcrt_157_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 06/22/2022] [Indexed: 02/21/2024]
Abstract
AIMS AND BACKGROUND In general, neoadjuvant treatment is the standard for clinical stage II/III esophageal cancer (EC), whereas the effect of adjuvant treatment on survival still remains controversial. The aim of this study was to investigate the efficacy of adjuvant treatment modalities on the survival of EC patients. PATIENTS AND METHODS A total of 63 patients with stage II-IVA EC who had undergone curative surgery between the years 2002 and 2020 were included in the study. Patients' data were retrospectively collected from oncologic follow-up files. Various treatment regimens were administered during this period, including chemotherapy and chemoradiotherapy. RESULTS The median age was 56 years (24-73), and the number of males was slightly higher than females (male/female: 33/30). While 32 (51%) patients received postoperative adjuvant treatment, the remaining 31 (49%) patients underwent surgery alone. The median overall survival (OS) was 45.9 months (95% confidence interval [CI]: 25.1-66.8) in patients receiving adjuvant therapy and 37.6 months (95% CI: 20.9-54.4) in patients not receiving adjuvant therapy. The 8.3-month survival difference was statistically insignificant (P = 0.54). The 1-, 3-, and 5-year OS rates were 87.5% versus 77.4%, 58.4% versus 51.6%, and 40.8% versus 27.6% for patients with and without adjuvant therapy, respectively. Pathological stage (P = 0.028) and lymph node status (P = 0.044) were significant prognostic factors for survival. CONCLUSIONS This study did not support the benefit of adjuvant treatment compared with surgery alone in completely resected EC patients. The reason for this result may be related to the small sample size and different treatment regimens due to the change in treatment options over time.
Collapse
Affiliation(s)
- Efnan Algin
- Department of Medical Oncology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
| | - Selin Akturk Esen
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Oznur Bal
- Department of Medical Oncology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
| |
Collapse
|
6
|
Bal O, Acikgoz Y, Yildiz B, Kos FT, Algin E, Dogan M. Simple and easily accessible prognostic markers in ewing sarcoma; neutrophil-lymphocyte ratio, neutrophil-platelet score and systemic-inflammation index. J Cancer Res Ther 2023; 19:1241-1247. [PMID: 37787290 DOI: 10.4103/jcrt.jcrt_1741_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
Background Inflammation markers are the new point of view in cancer due to increasing data on the interaction of immune system with tumor cells and their prognostic and predictive importance were found in many different types of solid tumors. Therefore, we aimed to evaluate the prognostic value of neutrophil-lymphocyte ratio (NLR), neutrophil-platelet score (NPS), and systemic inflammation index (SII) in Ewing sarcoma patients in which risk groups are still not clearly defined. Methods and Results A total of 64 patients were evaluated retrospectively. Receiver operating characteristic analysis was performed to find cut-off values for NLR and SII. Survival analysis was calculated by using Kaplan-Meier method. Cox regression analysis was performed to determine prognostic factors such as age, stage, and neoadjuvant chemotherapy were statistically significant prognostic factors for OS in multivariate analysis. While patients with low NLR and SII had longer OS (P = 0.003 and P = 0.018), patients with high NPS score had shorter OS (67.7 vs 21.7 months, P = 0.001). Conclusion Patients with lower NLR, NPS, and SII score have a better prognosis compared with those with higher NLR, NPS, and SII score and these simple parameters may be monitoring tools of the tumor microenvironment.
Collapse
Affiliation(s)
- Oznur Bal
- Department of Medical Oncology, University of Health Science, Ankara City Hospital, Ankara, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, University of Health Science, Ankara City Hospital, Ankara, Turkey
| | - Birol Yildiz
- Department of Medical Oncology, Gulhane Training and Research Hospital, Ankara, Turkey
| | - Fahriye T Kos
- Department of Medical Oncology, University of Health Science, Ankara City Hospital, Ankara, Turkey
| | - Efnan Algin
- Department of Medical Oncology, University of Health Science, Ankara City Hospital, Ankara, Turkey
| | - Mutlu Dogan
- Department of Medical Oncology, Dr. A.Y. Oncology Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
7
|
Acikgoz Y, Yildirim FU, Ergun Y, Ucar G, Aktürk Esen S, Bal O, Uncu D. The prognostic value of Sprouty2 protein in nonsmall cell lung cancer. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e20524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20524 Background: We represent Sprouty 2 (Sprty2) protein expression analysis and its association with key pathological and clinical features of pts with NSCLC as the largest ex-vivo data series. Methods: All IHC stainings were performed using a fully automated IHC staining device (Ventana BenchMark XT, Ventana Medical Systems, Tucson, AZ). Sprouty2 (Clone: AB_2720609, Cat. Number: PA5-7688; Dilution:1/100, ThermoFisher-Invitrogen) primer antibodies were used in IHC examination. Lung alveolar epithelium and bronchial mucosa were used as positive controls. Staining intensity [0 (no reaction), 1+ (weak reaction), 2+ (moderate reaction), 3+ (strong reaction)] and percentage of positively (PP) stained cells [0 (0%), 1 (< 10%), 2 (11-50%), 3 (51-90%), 4 (> 90%)] were analyzed together to calculate immunreactivity score (IRS) values ranging from 0 to 12. Results: 41 pts' sample were analyzed in this study. Sprty2 staining intensity and percentage were statistically significantly lower in tumor tissue (p < 0.0001). The number of pts with positive Sprty2 expression was 17 (42%) and negative was 24 (58%). The ratio of smoking status, brain and lypmh node metastasis were higher in Sprty2 positive group (Table). OS for patients with Sprty2 positive was lower than those with Sprty2 negative in metastatic patients (6.9 mo vs 13.6 mo, p = 0.023). Sprty2 positive pts had inferior survival compared to Sprty2 negative pts among those with AC histology (7.0 mo vs NR, p = 0.003). Conclusions: Sprty2 expression was decreased in tumor tissue compared to normal lung parenchyma. Paradoxically, Sprty2 positive patients had lower survival in certain subgroups (metastatic disease, AC) compared to those with negative pts. Sprty2 protein may be a new target especially for pts without druggable targets. [Table: see text]
Collapse
Affiliation(s)
- Yusuf Acikgoz
- Health Science University, Ankara City Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Fatma Unal Yildirim
- Health Science University, Ankara City Hospital, Department of Clinical Pathology, Ankara, Turkey
| | - Yakup Ergun
- Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Gokhan Ucar
- Ankara City Hospital Department of Medical Oncology, Ankara, Turkey
| | - Seli̇n Aktürk Esen
- Health Science University, Ankara City Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Oznur Bal
- Halth Science University, Ankara City Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Dogan Uncu
- Health Science University, Ankara City Hospital, Department of Medical Oncology, Ankara, Turkey
| |
Collapse
|
8
|
Ergun Y, Esen SA, Bardakci M, Ucar G, Kalkan Z, Urakci Z, Seyran E, Dogan M, Eren T, Aslan V, Kahraman S, Genc EE, Acikgoz Y, Dirikoc M, Esen I, Uncu D. Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors. Cancer Biomark 2022; 34:329-336. [PMID: 35001878 DOI: 10.3233/cbm-210455] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND The relationship of the ABO blood group system with the immune response is known, but its relationship with immune checkpoint inhibitors (ICIs) has not been clearly investigated until now. OBJECTIVE In this study, the relationship between different blood groups and nivolumab treatment response in patients with advanced malignant melanoma was investigated. METHODS The data of patients who used nivolumab for advanced malignant melanoma between April 2018 and April 2021 were retrospectively reviewed. RESULTS A total of 73 patients were included in the study. In the progression-free survival (PFS) analysis according to blood groups, it was 3.9 months, 16.1 months, 20.0 months and 3.0 months for A, B, AB and O, respectively (p= 0.1). Overall survival (OS) analysis according to blood groups was 5.1 months, 25.0 months, 20.0 months and 9.3 months for A, B, AB and O, respectively (p= 0.1). The B antigen group (B or AB) had significantly longer PFS and OS than the non-B antigen group (A or O) (16.1 vs. 3.5 months for PFS, respectively, p= 0.03; 20.0 vs. 7.4 months for OS, respectively, p= 0.02). CONCLUSIONS The presence of B antigen provides a significant advantage in terms of survival in patients using ICIs for advanced melanoma.
Collapse
Affiliation(s)
- Yakup Ergun
- Department of Medical Oncology, Batman Training and Research Hospital, Batman, Turkey
| | - Selin Akturk Esen
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Murat Bardakci
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Gokhan Ucar
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Ziya Kalkan
- Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey
| | - Zuhat Urakci
- Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey
| | - Erdogan Seyran
- Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Mutlu Dogan
- Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey
| | - Tulay Eren
- Department of Medical Oncology, UHS Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
| | - Volkan Aslan
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
| | - Seda Kahraman
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Emine Eylem Genc
- Department of Hematology, Batman Training and Research Hospital, Batman, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Merve Dirikoc
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Irfan Esen
- Department of Internal Medicine, VM Medical Park (Kecioren) Hospital, Ankara, Turkey
| | - Dogan Uncu
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| |
Collapse
|
9
|
Esen SA, Acikgoz Y, Bal O, Yildiz B, Ucar G, Dirikoc M, Ergun Y, Algin E, Uncu D. A Comparison of Osseous and Extraosseous Ewing Sarcoma. J Coll Physicians Surg Pak 2021; 31:27-33. [PMID: 33546529 DOI: 10.29271/jcpsp.2021.01.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 12/22/2020] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To compare the clinicopathological characteristics, treatment responses, survival analysis of osseous Ewing sarcoma (OES) and extraosseous ES (EES). STUDY DESIGN Observational study. PLACE AND DURATION OF STUDY Ankara City Hospital and Ankara Numune Training Research Hospital Medical Oncology Clinics from January 2005 to February 2020. METHODOLOGY Clinicopathological characteristics of histologically confirmed ES/PNET and followed up, and treatment modalities were recorded from patients' registration data-base of the hospital. Lactate dehydrogenase (LDH), alkaline phosphatase (ALP), hemoglobin were measured before chemotherapy or surgery. The patients with a second cancer, gall bladder/biliary tract diseases, viral hepatitis and other bone diseases were excluded. RESULTS Sixty seven patients evaluated retrospectively. Out of the total patients, 56.7% consisted of OES, and 43.3% consisted of EES. The median age of the EES group (26 years) was significantly higher than that of the OES group (22 years, p = 0.008). The most common metastasis region was lung in both the groups. Age, LDH levels and stage of the disease were found to be statistically significant prognostic factors in univariate and multivariate analysis. The median OS of patients who started with local treatment (surgical, surgical ± radiotherapy) and followed up with chemotherapy was 82.6 months (95% CI, 55.2-110.1), while the median OS of patients who received local treatment between or after chemotherapy was 43.4 months (95% CI, 13.2-73.6, p = 0.042). CONCLUSION Patients with extrosseus ES were significantly older. Age, LDH levels, stage of disease, local treatment followed by systemic therapy are important associated factors. Key Words: Osseous ewing sarcoma, Extraosseous ewing sarcoma, Chemotherapy, Local treatment.
Collapse
Affiliation(s)
- Selin Akturk Esen
- Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey
| | - Oznur Bal
- Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey
| | - Birol Yildiz
- Department of Medical Oncology, Elazığ Fethi Sekin City Hospital, Turkey
| | - Gokhan Ucar
- Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey
| | - Merve Dirikoc
- Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey
| | - Yakup Ergun
- Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey
| | - Efnan Algin
- Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey
| | - Dogan Uncu
- Department of Medical Oncology, Health Sciences University, Ankara City Hospital, Ankara, Turkey
| |
Collapse
|
10
|
Acikgoz Y, Aktürk Esen S, Ucar G, Dirikoc M, Ergun Y, Bal O, Uncu D. The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer. Cureus 2021; 13:e14882. [PMID: 34104608 PMCID: PMC8179973 DOI: 10.7759/cureus.14882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Introduction: Fluoropyrimidine and platinum-based chemotherapy regimens are widely accepted for metastatic gastric cancer (GC). Because of drug toxicity, a combined two-drug cytotoxic drug regimen is recommended for first-line therapy, while three-drug cytotoxic regimens are recommended for patients with medically fit and better performance status. In this study, it was aimed to compare modified FOLFOX-6 (mFOLFOX-6) and modified DCF (mDCF) regimens in terms of survival and side effects in first-line treatment in metastatic GC. Methods: We retrospectively reviewed the clinical record of patients with metastatic gastric or gastro-esophageal junction cancer who had received mDCF or mFOLFOX-6 as the first-line treatment, and followed up in our center between February 2013 and December 2020. The data were collected from the patients' registration database of the hospital and oncologic follow-up files of our center. In the mDCF arm, docetaxel 60 mg/m2 and cisplatin 60 mg/m2 on day 1 intravenous (i.v.) infusion, and 600 mg/m2 5-fluorouracil (FU) as a continuous infusion for five days were administrated every three weeks for up to six cycles. In the mFOLFOX-6 arm, 85 mg/m2 oxaliplatin and 400 mg/m2 LV as an i.v. infusion over two hours and a 5-FU bolus of 400 mg/m2 as a 10-minute infusion, followed by 2.400 mg/m2 5-FU as a 46-hour continuous infusion were administrated every two weeks for up to six cycles. Univariate and multivariate analyses for overall survival (OS) were performed by Cox proportional hazards regression model. Survival analysis was performed by the Kaplan-Meier method with the Long-rank test. P-value <0.05 was considered statistically significant. Results: A total of 70 patients included into the study. Of those, 40 (57%) patients had received mDCF and 30 (43%) had received FOLFOX-6 regimens as first-line treatment. There were no complete responses in both groups. The partial response rate was 28% and 27% for mDCF and mFOLFOX-6, respectively. There was no statistically significant difference regarding treatment response for both groups (p=0.787). The median OS was 13.9 months (95% CI: 7.5-20.4) in the mDCF arm, and 10.4 months (95% CI: 6.4-14.4) in the mFOLFOX-6 arm (p=0.409). The median progression-free survival (PFS) was 5.2 months (95% CI: 3.6-6.9) in the mDCF arm, and 6.4 months (3.2-9.6) in the FOLFOX-6 arm (p=0.126). The ratio of dose reduction, treatment delay, and neutropenic fever were not statistically different between treatment arms. Conclusion: The present study demonstrated that proper patient selection for metastatic GC may give rise to comparable survival rates without increased toxicity. mFOLFOX-6 and mDCF had similar response rates, OS, PFS, and side effect profiles.
Collapse
Affiliation(s)
- Yusuf Acikgoz
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Selin Aktürk Esen
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Gokhan Ucar
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Merve Dirikoc
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Yakup Ergun
- Medical Oncology, Batman City Hospital, Batman, TUR
| | - Oznur Bal
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Dogan Uncu
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| |
Collapse
|
11
|
Ergun Y, Esen SA, Ucar G, Acikgoz Y, Karacin C. Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic? JCO Oncol Pract 2021; 17:455-456. [PMID: 33797950 DOI: 10.1200/op.20.01091] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Yakup Ergun
- Yakup Ergun, MD, Medical Oncology Unit, Batman Training and Research Hospital, Batman, Turkey; Selin Akturk Esen, MD, Gokhan Ucar, MD, Yusuf Acikgoz, MD, Medical Oncology Unit, Ankara City Hospital, Ankara, Turkey; and Cengiz Karacin, MD, Medical Oncology Unit, RTE Training and Research Hospital, Rize, Turkey
| | - Selin Akturk Esen
- Yakup Ergun, MD, Medical Oncology Unit, Batman Training and Research Hospital, Batman, Turkey; Selin Akturk Esen, MD, Gokhan Ucar, MD, Yusuf Acikgoz, MD, Medical Oncology Unit, Ankara City Hospital, Ankara, Turkey; and Cengiz Karacin, MD, Medical Oncology Unit, RTE Training and Research Hospital, Rize, Turkey
| | - Gokhan Ucar
- Yakup Ergun, MD, Medical Oncology Unit, Batman Training and Research Hospital, Batman, Turkey; Selin Akturk Esen, MD, Gokhan Ucar, MD, Yusuf Acikgoz, MD, Medical Oncology Unit, Ankara City Hospital, Ankara, Turkey; and Cengiz Karacin, MD, Medical Oncology Unit, RTE Training and Research Hospital, Rize, Turkey
| | - Yusuf Acikgoz
- Yakup Ergun, MD, Medical Oncology Unit, Batman Training and Research Hospital, Batman, Turkey; Selin Akturk Esen, MD, Gokhan Ucar, MD, Yusuf Acikgoz, MD, Medical Oncology Unit, Ankara City Hospital, Ankara, Turkey; and Cengiz Karacin, MD, Medical Oncology Unit, RTE Training and Research Hospital, Rize, Turkey
| | - Cengiz Karacin
- Yakup Ergun, MD, Medical Oncology Unit, Batman Training and Research Hospital, Batman, Turkey; Selin Akturk Esen, MD, Gokhan Ucar, MD, Yusuf Acikgoz, MD, Medical Oncology Unit, Ankara City Hospital, Ankara, Turkey; and Cengiz Karacin, MD, Medical Oncology Unit, RTE Training and Research Hospital, Rize, Turkey
| |
Collapse
|
12
|
Acikgoz Y, Bal O, Ucar G, Durnali A, Ergun Y, Dirikoc M, Esen SA, Dogan M. Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity? Expert Opin Drug Saf 2021; 20:611-621. [PMID: 33605170 DOI: 10.1080/14740338.2021.1893304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
BACKGROUND: We aim to explore the predictive role of clinical and hematological parameters for cetuximab-induced skin toxicity (CI-ST) and survival outcomes in patients according to risk categories.RESEARCH DESIGN AND METHODS: The optimal cut-off values for hematological parameters were assessed by the Receiver Operating Characteristic (ROC) analysis. Patients were classified as High risk, Intermediate risk and Low risk subgroups with respect to platelet to lymphocyte ratio (PLR) and red blood cell count (RBC) values. Kaplan-Meier test was used for survival analysis, and outcomes were analyzed by Log-rank test. P-value <0.05 considered as statistically significant.RESULTS: Among hematological parameters, only PLR and RBC were statistically significant prognostic factors.Optimal cut-off value for PLR was 196.2 (82.9% sensitivity and 61.1% specificity), and 4.610x106/µL for RBC count (65.9% sensitivity and 81.1% specificity). Patients in high risk group had increased risk with an OR:69.34 (p<0.0001), and in the intermediate risk group had an OR:28.73 (p=0.002) for CI-ST. De novo metastatic patients had 9.11-fold increased risk for CI-ST compared to recurrent metastatic patients (p=0.028).CONCLUSION: Our study indicates that risk categories based on PLR and RBC can predict CI-ST and de novo metastatic patients had higher risk for CI-ST.
Collapse
Affiliation(s)
- Yusuf Acikgoz
- Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey
| | - Oznur Bal
- Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey
| | - Gokhan Ucar
- Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey
| | - Ayse Durnali
- Ankara Dr AY Oncology Training and Research Hospital Department of Medical Oncology, Turkey
| | - Yakup Ergun
- Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey
| | - Merve Dirikoc
- Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey
| | - Selin Akturk Esen
- Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey
| | - Mutlu Dogan
- Ankara Dr AY Oncology Training and Research Hospital Department of Medical Oncology, Turkey
| |
Collapse
|
13
|
Karacin C, Acar R, Bal O, Eren T, Sendur MAN, Acikgoz Y, Karadurmus N, Imamoglu GI, Oksuzoglu OB, Dogan M. "Swords and Shields" against COVID-19 for patients with cancer at "clean" and "pandemic" hospitals: are we ready for the second wave? Support Care Cancer 2021; 29:4587-4593. [PMID: 33479795 PMCID: PMC7819771 DOI: 10.1007/s00520-021-06001-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 01/12/2021] [Indexed: 12/13/2022]
Abstract
Purpose COVID-19 will continue to disrupt the diagnosis-treatment process of cancer patients. Dr. Abdurrahman Yurtaslan Ankara Oncology Hospital has been considered as a ‘non-pandemic’ center (‘clean’) in Ankara, the capital city of Turkey. The other state hospitals that also take care of cancer patients in Ankara were defined as ‘pandemic’ centers. This study aimed to evaluate hospital admission changes and the precautionary measures in clean and pandemic centers during the pandemic. The effect of these measures and changes on COVID-19 spreading among cancer patients was also evaluated. Methods The patients admitted to the medical oncology follow-up, new diagnosis, or chemotherapy (CT) outpatient clinics during the first quarter of pandemic period (March 15–June 1, 2020) of each center were determined and compared with the admissions of the same frame of previous year (March 15–June 1, 2019). COVID-19 PCR test results in clean and pandemic centers were compared with each other. Telemedicine was preffered in the clean hospital to keep on follow-up of the cancer patients as ‘noninfected’. Results In the clean hospital, COVID-19-infected patients that needed to be hospitalized were referred to pandemic hospitals. COVID-19 test positivity rate was eight-fold higher for outpatient clinic admissions in pandemic hospitals (p < 0.001). The number of patients admitted new diagnosis outpatient clinics in both clean and pandemic hospitals decreased significantly during the pandemic compared with the previous year. Conclusion We consider that local strategic modifications and defining ‘clean’ hospital model during infectious pandemic may contribute to protect and treat cancer patients during pandemic.
Collapse
Affiliation(s)
- Cengiz Karacin
- Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, 06200, Ankara, Yenimahalle, Turkey.
| | - Ramazan Acar
- Department of Medical Oncology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Oznur Bal
- Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey
| | - Tulay Eren
- Department of Medical Oncology, Diskapi Yildirim Beyazit Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Mehmet Ali Nahit Sendur
- Department of Medical Oncology, Ankara City Hospital, Yildirim Beyazit University, Ankara, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey
| | - Nuri Karadurmus
- Department of Medical Oncology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Goksen Inanc Imamoglu
- Department of Medical Oncology, Diskapi Yildirim Beyazit Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Omur Berna Oksuzoglu
- Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, 06200, Ankara, Yenimahalle, Turkey
| | - Mutlu Dogan
- Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, 06200, Ankara, Yenimahalle, Turkey
| |
Collapse
|
14
|
Acikgoz Y, Bal O, Ergun Y, Oksuzoglu B, Yildiz B, Doğan M. Systemic treatment options for growing teratoma syndrome: A single-center experience with a comprehensive review of the literature. J Cancer Res Ther 2021; 17:75-79. [PMID: 33328389 DOI: 10.4103/jcrt.jcrt_568_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background Growing teratoma syndrome (GTS) is a very uncommon phenomena. Given its lower prevalence, there is little data about clinichopathological features and management of GTS. Literature about disease mostly composed of case reports. In this study, we aimed to report patients characteristics and treatment modalities in our center within a relatively large cohort. Patients and Methods We retrospectively reviewed the clinical records 21 patients who fulfilled criteria of GTS. Survival analysis was performed by using the Kaplan-Meier method with the Long-rank test. p<0.05 was considered statistically significant. Results The median age at diagnosis was 25 (range 17-51). A total of 12 patients could have undergone surgery. Of patients who underwent surgery, 5 patients remained fully disease free, and 7 patients had experienced disease recurrences. Nine patients had unresectable disease, and treated with either platin-based chemotherapy or interferone α2b. Of those, 5 patients eventually had undergone autologous stem cell transplantation (ASCT) with surprisingly promising response rates. One patient had complete response and three patients had partial response. One patient died soon after ASCT due to infectious complication. Conclusion GTS is an unique entity with regard to its clinicopathological features and available treatment options as we mentioned in the text. Despite various agents reported to have efficacy in case reports, surgery remains as the mainstay of treatment. According to result of our study, ASCT and platin-based chemotherapy regimens may be feasible options for patients with unresectable disease.
Collapse
Affiliation(s)
- Yusuf Acikgoz
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Oznur Bal
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Yakup Ergun
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Berna Oksuzoglu
- Department of Medical Oncology, Ankara Dr AY Oncology Training and Research Hospital, Ankara, Turkey
| | - Birol Yildiz
- Department of Medical Oncology, Elazig City Hospital, Elazig, Turkey
| | - Mutlu Doğan
- Department of Medical Oncology, Ankara Dr AY Oncology Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
15
|
Abstract
OBJECTIVES Neuroendocrine tumors (NETs) are very heterogeneous tumors. This study aimed to evaluate prognostic value of an albumin-to-alkaline phosphatase (ALP) ratio (AAPR) in well-differentiated NETs. METHODS A total of 110 patients were included in this study. Albumin-to-alkaline phosphatase ratio was calculated by dividing albumin concentration (g/dL) to ALP level (U/L). Cutoff value for AAPR was determined by receiver operating characteristic analysis. Survival analysis was performed by Kaplan-Meier method with the log-rank test. A P value of less than 0.05 was considered statistically significant. RESULTS The optimum cutoff value for AAPR was 0.028. Patients were divided into 2 groups as patients with AAPR of 0.028 or less (n = 22, 20%) and with AAPR of greater than 0.028 (n = 88, 80%). Patients with AAPR of greater than 0.028 had statistically longer overall survival compared with patients with 0.028 or less (not reached vs 96.8 months, P = 0.001). In addition, AAPR has been shown to be an independent prognostic factor for overall survival in multivariate analysis (hazard ratio, 3.99; 95% confidence interval, 1.26-12.61, P = 0.018). CONCLUSIONS Patients with higher AAPR had more favorable prognosis compared with patients with lower AAPR. We demonstrated that AAPR can be of prognostic value in well-differentiated NETs.
Collapse
Affiliation(s)
- Yusuf Acikgoz
- From the Department of Medical Oncology, Health Science University, Ankara City Hospital
| | - Oznur Bal
- From the Department of Medical Oncology, Health Science University, Ankara City Hospital
| | - Mutlu Dogan
- Department of Medical Oncology, Ankara Dr AY Oncology Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
16
|
Ucar G, Acikgoz Y, Ergun Y, Eren T, Dirikoc M, Esen SA, Yazıcı O, Uncu D, Ozdemir NY. Prognostic and Predictive Value of NAR Score in Gastric Cancer. J Gastrointest Cancer 2020; 52:1054-1060. [PMID: 33064272 DOI: 10.1007/s12029-020-00537-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/12/2020] [Indexed: 12/24/2022]
Abstract
INTRODUCTION Neoadjuvant treatment is a widely accepted approach for locally advanced rectum cancer. Efforts to explore a surrogate endpoint for clinical trials revealed a new prognostic scoring system which is named as neoadjuvant rectal score (NAR) in patients who received neoadjuvant treatment for rectal cancer. MATERIAL AND METHODS 88 patients who met inclusion criteria were included in the study. The optimal cutoff value of the NAR score was 17.6 with 71% sensitivity and 63% specificity. Patients with NAR score > 17.6 (n: 48, 54%) were defined as the high-risk group and those with NAR score ≤ 17.6 (n: 40, 56%) as the low-risk group. RESULT Survival analysis according to the NAR score group (low-risk vs high-risk) revealed that there was a statistically significant difference between groups regarding OS and DFS. The median OS for high-risk patients was 27.3 months (95% CI, 15.0-39.6); it was 76.6 months (47.3-106.0) for low-risk patients (p < 0.0001). The median DFS was 15.1 months (11.8-18.4) for high-risk patients; it was 44.3 months (95% CI, 4.1-84.6) in the low-risk group (p = 0.002). DISCUSSION As a result, we interpreted our findings as supporting data about the utility of NAR score not only as a surrogate endpoint for the clinical trial of rectal cancer but also as a prognostic marker in patients with gastric cancer who received neoadjuvant treatment.
Collapse
Affiliation(s)
- Gokhan Ucar
- Medical Oncology, Ankara City Hospital, Ankara, Turkey.
| | - Yusuf Acikgoz
- Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Yakup Ergun
- Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Tulay Eren
- Medical Oncology, Yıldırım Beyazıt Dışkapı Training and Research Hospital, Ankara, Turkey
| | - Merve Dirikoc
- Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | | | - Ozan Yazıcı
- Medical Oncology, Medicine Faculty of Gazi University, Ankara, Turkey
| | - Dogan Uncu
- Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | | |
Collapse
|
17
|
Abstract
Colorectal cancer (CRC) is the third most common cancer in the world and is the second leading cause of cancer-related deaths. Several mutations are involved in the development of CRC. The prognostic significance of the KRAS mutation has been discussed in many studies. We aimed to investigate the prognostic significance of the number of KRAS mutations in metastatic CRC (mCRC).Patients with mutations in the KRAS gene were included in the study. They were divided into 2 groups as single mutation and multiple mutations in the KRAS gene.For the study, 425 CRC patients were screened. KRAS mutation was positive in 191 patients (45%). One hundred ninety-one patients were included in the study, 171 patients (90%) had single mutations and 20 patients (10%) had multiple mutations. Median progression-free survival was 12.8 months in patients with multiple mutations, while it was 8.8 months in patients with single mutations (P: .05). The median overall survival of patients with multiple mutations was 40.7 months, while it was 22.7 months for patients with single mutations (P = .01)We found that the presence of multiple mutations in KRAS mutant patients was associated with better overall survival and progression-free survival than a single mutation.
Collapse
Affiliation(s)
- Gokhan Ucar
- Department of Medical Oncology, Ankara City Hospital, Ankara
| | - Yakup Ergun
- Department of Medical Oncology, Ankara City Hospital, Ankara
| | | | - Yusuf Acikgoz
- Department of Medical Oncology, Ankara City Hospital, Ankara
| | - Merve Dirikoc
- Department of Medical Oncology, Ankara City Hospital, Ankara
| | - İrfan Esen
- Department of Internal Medicine, Yenimahalle Training and Education Hospital, Ankara, Turkey
| | - Öznur Bal
- Department of Medical Oncology, Ankara City Hospital, Ankara
| | - Doğan Uncu
- Department of Medical Oncology, Ankara City Hospital, Ankara
| |
Collapse
|
18
|
Ucar G, Acikgoz Y, Ergun Y, Bal O, Yilmaz M, Karakaya S, Akdeniz N, Kostek O, Aydin Isak O, Yazici Sener G, Dirikoc M, Aktürk Esen S, Dogan M, Uncu D. Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma? Cureus 2020; 12:e10525. [PMID: 33094066 PMCID: PMC7574822 DOI: 10.7759/cureus.10525] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-nivolumab tyrosine kinase inhibitors (TKIs). Material and methods The analysis of patients was performed after all cohorts were sub-grouped into two groups according to pre-nivolumab TKIs as following the sunitinib arm and the pazopanib arm. Result A total of 75 patients were included in this study. The median follow-up time was eight months for all cohorts. The objective response rate was statistically significantly higher in the pazopanib arm as compared to the sunitinib arm (56% vs 30%, p=0.02). Progression-free survival was significantly higher in pazopanib than sunitinib (10.3 months vs 5.3 months, p=0.02). Multivariate analysis revealed that pazopanib treatment was associated with better progression-free survival (HR: 0.44, 95 CI; 0.22-0.91, p=0.02). While the median overall survival for patients who had received sunitinib was 11.0 months, it has not been reached the median in the pazopanib arm (11.0 months vs NR, p=0.051). Discussion We demonstrated significantly better progression-free survival and a higher objective response rate with nivolumab treatment in patients who had received pazopanib as compared with patients who received sunitinib in the pre-nivolumab period.
Collapse
Affiliation(s)
- Gokhan Ucar
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Yusuf Acikgoz
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Yakup Ergun
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Oznur Bal
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Mesut Yilmaz
- Medical Oncology, Bakırkoy Sadi Konuk Training and Research Hospital, Istanbul, TUR
| | - Serdar Karakaya
- Medical Oncology, Health of Science Abdurrahman Yurtaslan Training and Research Hospital, Ankara, TUR
| | - Nadiye Akdeniz
- Medical Oncology, Dicle University Medical Faculty, Diyarbakır, TUR
| | - Osman Kostek
- Medical Oncology, Trakya University Medical Faculty, Edirne, TUR
| | - Ozlem Aydin Isak
- Medical Oncology, Health of Science Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, TUR
| | | | - Merve Dirikoc
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Selin Aktürk Esen
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| | - Mutlu Dogan
- Medical Oncology, Health of Science Abdurrahman Yurtaslan Training and Research Hospital, Ankara, TUR
| | - Dogan Uncu
- Medical Oncology, Health of Science Ankara City Hospital, Ankara, TUR
| |
Collapse
|
19
|
Dogan M, Guresci S, Acikgoz Y, Ergun Y, Kos FT, Bozdogan O, Bal O. Is there any correlation among MKK4 (mitogen-activated protein kinase kinase 4) expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer. Expert Rev Mol Diagn 2020; 20:851-859. [PMID: 32552144 DOI: 10.1080/14737159.2020.1784728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND We aimed to evaluate the correlation between MKK4 expression and clinicopathological features, KRAS/NRAS mutation in colorectal cancer. METHODS MKK4 expression was assessed by immunoreactivity score (IRS). Staining intensity(SI) and percentage of positively stained cells (PP) were used for IRS (IRS = SI×PP). Cutoffs were explored with ROC analysis. Patients were grouped as WIR ('weak immunoreactive'; IRS:0-2) and SIR ('strong immunoreactive'; IRS: >3). RESULTS We enrolled 95 patients. 63.2% had metastasis. Median follow-up was 31.4 months. KRAS/NRAS mutation rate was 45.2%. Median values for OS, DFS, and PFS were as 31.6, 17.2, and 10.3 months. WIR group had longer OS (p = 0.03). Recurrence rate was 36.8%. Median DFS was longer for recurrent patients in WIR group (p = 0.055). KRAS or NRAS wild-type patients and those with left-sided tumors in WIR group had longer OS (p = 0.029, p = 0.024, p = 0.03). There was no PFS difference (p: 0.15). In correlation analysis, there was a negative correlation between MKK4 expression and KRAS mutation, NRAS mutation, OS, PFS, DFS (r: -0,06; r: -0,02; r: -0,10; r: -0,06; r: -0,34). Only the correlation for MKK4 expression and DFS was significant (p = 0.04). CONCLUSION MKK4 expression inversely correlates with survival outcomes. Patients with KRAS/NRAS wild-type, left-sided tumors with WIR had longer OS.
Collapse
Affiliation(s)
- Mutlu Dogan
- Department of Medical Oncology, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital , Ankara, Turkey
| | - Servet Guresci
- Department of Pathology, Ankara Numune Training and Research Hospital , Ankara, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, Ankara Numune Training and Research Hospital , Ankara, Turkey
| | - Yakup Ergun
- Department of Medical Oncology, Ankara Numune Training and Research Hospital , Ankara, Turkey
| | - Fahriye Tugba Kos
- Department of Medical Oncology, Lokman Hekim Medical Center , Ankara, Turkey
| | - Onder Bozdogan
- Department of Pathology, Gulhane Training and Research Hospital , Ankara, Turkey
| | - Oznur Bal
- Department of Medical Oncology, Ankara Numune Training and Research Hospital , Ankara, Turkey
| |
Collapse
|
20
|
Ucar G, Ergun Y, Acikgoz Y, Uncu D. The prognostic value of the prognostic nutritional index in patients with metastatic colorectal cancer. Asia Pac J Clin Oncol 2020; 16:e179-e184. [PMID: 32301263 DOI: 10.1111/ajco.13328] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Accepted: 02/02/2020] [Indexed: 01/04/2023]
Abstract
OBJECTIVE The prognostic nutritional index (PNI) has been shown to be prognostic value for many types of cancer of the gastrointestinal system. However, there are limited data on its value for metastatic colorectal cancer (mCRC). This study aimed to evaluate the prognostic value of PNI in newly diagnosed mCRC patients. METHODS The data of 468 patients who had been admitted to our center upon being diagnosed with mCRC between January 2010 and December 2017 were reviewed retrospectively, whereby satisfying the inclusion criteria were included in the study. Receiver operating characteristic (ROC) analysis was used for PNI's optimum cut-off value for overall survival (OS). The Cox regression model was used in the single-variable analysis in order to test whether or not variables with prognostic properties were independent prognostic factors. FINDINGS A total of 308 patients were included in the study. Sixty-two percent (n = 192) of the patients were males, and the median age was 57.5 years (range: 25-83). Forty-five percent (n = 137) of the patients had KRAS mutation. Tumors localized in the colon accounted for 63% (n = 193) of the patients. The liver was the most common region of metastasis at 69%. According to the ROC curve, the optimal cut-off value for PNI was 46 (sensitivity 74%, specificity 47%, AUC 0.615, 95% confidence interval [CI]: 0.54-0.68, P = .002). One hundred and eighty-two patients (59%) fell into the PNI-High (> 46) group, while 126 patients (41%) fell into the PNI-Low (≤ 46) group. The rectum localization was higher, whereas the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were lower in the PNI-High group. There was no difference in terms of other patient characteristics. The median OS was significantly longer in the PNI-High group compared to the PNI-Low group (28.4 vs 19.1 months, P < .001). The Cox regression analysis showed that a high PNI was an independent positive prognostic factor (hazard ratio: 0.61, 95% CI: 0.42-0.87, P = .007). DISCUSSION We found PNI to be an independent prognostic factor in mCRC. We think that PNI, which can be calculated by a simple formula, may provide clinicians important clues in order to make desicion for individual treatment.
Collapse
Affiliation(s)
- Gokhan Ucar
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Yakup Ergun
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| | - Dogan Uncu
- Department of Medical Oncology, University of Health Sciences Ankara City Hospital, Ankara, Turkey
| |
Collapse
|
21
|
Ergun Y, Bal O, Dogan M, Ucar G, Dirikoc M, Acikgoz Y, Bacaksiz F, Uncu D. Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer? J Res Med Sci 2020; 25:14. [PMID: 32174986 PMCID: PMC7053176 DOI: 10.4103/jrms.jrms_1056_18] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Revised: 02/15/2019] [Accepted: 11/22/2019] [Indexed: 12/17/2022]
Abstract
BACKGROUND Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) has not been suggested by guidelines, since new systemic chemotherapy options have improved overall survival. However, the effect of PTR is still controversial in mCRC. In this study, we aimed to evaluate the effect of PTR on survival in unresectable mCRC. MATERIALS AND METHODS Two hundred and fifty-two patients with unresectable mCRC were screened retrospectively between January 2007 and December 2017 and a total of 147 patients who met inclusion criteria were included. The patients with emergency or elective PTR and the patients without surgery were compared for baseline features and overall survival. RESULTS The median follow-up time was 15.6 months (range; 1.2-78.9) in whole patients. There were 91 patients in nonsurgical (NS) group and 56 patients in PTR group. The median overall survival was significantly longer in PTR group compared NS group (21.8 vs. 17.0 months, P = 0.01), but it was not associated to better overall survival in multivariate Cox analysis (hazard ratio: 0.65, 95% confidence interval: 0.41-1.02, P = 0.06). There was no significant difference in overall survival between emergency and elective surgery subgroups (22.9 vs. 16.1 months, respectively, P = 0.9). CONCLUSION PTR did not offer an overall survival benefit in this study. Although it is debated, we think that it is better to start treatment with chemotherapy and biological agent combinations in patients with asymptomatic mCRC. Thus, the patients can be protected from the morbidity and mortality of the surgery.
Collapse
Affiliation(s)
- Yakup Ergun
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Oznur Bal
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Mutlu Dogan
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Gokhan Ucar
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Merve Dirikoc
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| | - Ferhat Bacaksiz
- Department of Gastroenterology, Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey
| | - Dogan Uncu
- Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
22
|
Ergun Y, Acikgoz Y, Bal O, Ucar G, Dirikoc M, Caliskan Yildirim E, Akdeniz N, Uncu D. KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer. Expert Rev Mol Diagn 2019; 19:1131-1140. [PMID: 31718325 DOI: 10.1080/14737159.2019.1693266] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Background: In this study, we aimed to investigate the frequency, prognostic effect of codon, and amino acid-specific KRAS mutations in patients with metastatic colorectal cancer (mCRC) and their predictive effect on irinotecan and oxaliplatin during first-line treatment.Methods: The data of 304 mCRC patients were retrospectively evaluated between 2010 and 2018. Patients were categorized according to the most prominent codon and amino acid mutation and their prognostic features were analyzed.Results: In total, 274 patients were included in the study and 128 patients (47%) revealed KRAS mutation. Median follow-up time was 19.8 months (range; 1.6-96). The median overall survival rates for patients with codons 12 and 13 mutations were 25.4 and 22.2 months, respectively (p = 0.4). Moreover, the median overall survival for the codon 12 mutant patients who received irinotecan-based chemotherapy in the first-line treatment was 42.7 months, whereas for the codon 13 mutant and KRAS wild-type patients, it was 18.3 and 23.9 months, respectively (codon 12 vs. codon 13; HR: 0.31, p = 0.03, codon 12 vs. wild-type; HR: 0.45, p = 0.03).Conclusion: The significant survival advantage was observed in patients with codon 12 mutations who received irinotecan-based chemotherapy as a first-line treatment.
Collapse
Affiliation(s)
- Yakup Ergun
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Yusuf Acikgoz
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Oznur Bal
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Gokhan Ucar
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Merve Dirikoc
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | | | - Nadiye Akdeniz
- Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - Dogan Uncu
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| |
Collapse
|